vs
Side-by-side financial comparison of ACADIA PHARMACEUTICALS INC (ACAD) and CATHAY GENERAL BANCORP (CATY). Click either name above to swap in a different company.
ACADIA PHARMACEUTICALS INC is the larger business by last-quarter revenue ($284.0M vs $222.8M, roughly 1.3× CATHAY GENERAL BANCORP). CATHAY GENERAL BANCORP runs the higher net margin — 653.4% vs 96.3%, a 557.1% gap on every dollar of revenue. On growth, CATHAY GENERAL BANCORP posted the faster year-over-year revenue change (19.5% vs 9.4%). Over the past eight quarters, ACADIA PHARMACEUTICALS INC's revenue compounded faster (17.5% CAGR vs 12.8%).
Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Del Mar, San Diego, California.
Cathay General Bancorp is a U.S.-headquartered bank holding company that operates Cathay Bank, offering full-spectrum commercial and personal banking services. It primarily serves Asian American communities and small-to-medium enterprises across major U.S. states including California, New York and Texas, as well as select Asian markets, with products covering deposits, loans, and wealth management solutions.
ACAD vs CATY — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $284.0M | $222.8M |
| Net Profit | $273.6M | $90.5M |
| Gross Margin | 90.8% | — |
| Operating Margin | 6.1% | 50.9% |
| Net Margin | 96.3% | 653.4% |
| Revenue YoY | 9.4% | 19.5% |
| Net Profit YoY | 90.3% | 12.9% |
| EPS (diluted) | $1.61 | $1.33 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $284.0M | $222.8M | ||
| Q3 25 | $278.6M | $210.6M | ||
| Q2 25 | $264.6M | $196.6M | ||
| Q1 25 | $244.3M | $187.8M | ||
| Q4 24 | $259.6M | $186.5M | ||
| Q3 24 | $250.4M | $189.5M | ||
| Q2 24 | $242.0M | $178.5M | ||
| Q1 24 | $205.8M | $175.2M |
| Q4 25 | $273.6M | $90.5M | ||
| Q3 25 | $71.8M | $77.7M | ||
| Q2 25 | $26.7M | $77.5M | ||
| Q1 25 | $19.0M | $69.5M | ||
| Q4 24 | $143.7M | $80.2M | ||
| Q3 24 | $32.8M | $67.5M | ||
| Q2 24 | $33.4M | $66.8M | ||
| Q1 24 | $16.6M | $71.4M |
| Q4 25 | 90.8% | — | ||
| Q3 25 | 92.2% | — | ||
| Q2 25 | 92.2% | — | ||
| Q1 25 | 91.7% | — | ||
| Q4 24 | 91.6% | — | ||
| Q3 24 | 92.5% | — | ||
| Q2 24 | 92.5% | — | ||
| Q1 24 | 88.8% | — |
| Q4 25 | 6.1% | 50.9% | ||
| Q3 25 | 12.8% | 44.5% | ||
| Q2 25 | 12.2% | 49.0% | ||
| Q1 25 | 7.9% | 46.1% | ||
| Q4 24 | 59.1% | 46.5% | ||
| Q3 24 | 12.6% | 41.2% | ||
| Q2 24 | 12.6% | 40.7% | ||
| Q1 24 | 7.4% | 45.7% |
| Q4 25 | 96.3% | 653.4% | ||
| Q3 25 | 25.8% | 36.9% | ||
| Q2 25 | 10.1% | 39.4% | ||
| Q1 25 | 7.8% | 37.0% | ||
| Q4 24 | 55.4% | 587.9% | ||
| Q3 24 | 13.1% | 35.6% | ||
| Q2 24 | 13.8% | 37.4% | ||
| Q1 24 | 8.0% | 40.8% |
| Q4 25 | $1.61 | $1.33 | ||
| Q3 25 | $0.42 | $1.13 | ||
| Q2 25 | $0.16 | $1.10 | ||
| Q1 25 | $0.11 | $0.98 | ||
| Q4 24 | $0.86 | $1.11 | ||
| Q3 24 | $0.20 | $0.94 | ||
| Q2 24 | $0.20 | $0.92 | ||
| Q1 24 | $0.10 | $0.98 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $177.7M | — |
| Total DebtLower is stronger | — | $119.1M |
| Stockholders' EquityBook value | $1.2B | $2.9B |
| Total Assets | $1.6B | $24.2B |
| Debt / EquityLower = less leverage | — | 0.04× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $177.7M | — | ||
| Q3 25 | $258.0M | — | ||
| Q2 25 | $253.6M | — | ||
| Q1 25 | $217.7M | — | ||
| Q4 24 | $319.6M | — | ||
| Q3 24 | $155.1M | — | ||
| Q2 24 | $177.1M | — | ||
| Q1 24 | $204.7M | — |
| Q4 25 | — | $119.1M | ||
| Q3 25 | — | $119.1M | ||
| Q2 25 | — | $119.1M | ||
| Q1 25 | — | $119.1M | ||
| Q4 24 | — | $119.1M | ||
| Q3 24 | — | $119.1M | ||
| Q2 24 | — | $119.1M | ||
| Q1 24 | — | $119.1M |
| Q4 25 | $1.2B | $2.9B | ||
| Q3 25 | $917.3M | $2.9B | ||
| Q2 25 | $822.4M | $2.9B | ||
| Q1 25 | $765.2M | $2.9B | ||
| Q4 24 | $732.8M | $2.8B | ||
| Q3 24 | $577.2M | $2.8B | ||
| Q2 24 | $516.7M | $2.8B | ||
| Q1 24 | $464.0M | $2.8B |
| Q4 25 | $1.6B | $24.2B | ||
| Q3 25 | $1.3B | $24.1B | ||
| Q2 25 | $1.2B | $23.7B | ||
| Q1 25 | $1.1B | $23.2B | ||
| Q4 24 | $1.2B | $23.1B | ||
| Q3 24 | $976.9M | $23.3B | ||
| Q2 24 | $914.1M | $23.2B | ||
| Q1 24 | $855.1M | $23.4B |
| Q4 25 | — | 0.04× | ||
| Q3 25 | — | 0.04× | ||
| Q2 25 | — | 0.04× | ||
| Q1 25 | — | 0.04× | ||
| Q4 24 | — | 0.04× | ||
| Q3 24 | — | 0.04× | ||
| Q2 24 | — | 0.04× | ||
| Q1 24 | — | 0.04× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-48.7M | $368.6M |
| Free Cash FlowOCF − Capex | — | $363.7M |
| FCF MarginFCF / Revenue | — | 163.2% |
| Capex IntensityCapex / Revenue | — | 2.2% |
| Cash ConversionOCF / Net Profit | -0.18× | 4.07× |
| TTM Free Cash FlowTrailing 4 quarters | — | $672.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-48.7M | $368.6M | ||
| Q3 25 | $74.3M | $150.6M | ||
| Q2 25 | $64.0M | $64.0M | ||
| Q1 25 | $20.3M | $99.0M | ||
| Q4 24 | $40.4M | $329.2M | ||
| Q3 24 | $63.2M | $81.2M | ||
| Q2 24 | $25.0M | $72.9M | ||
| Q1 24 | $29.1M | $88.2M |
| Q4 25 | — | $363.7M | ||
| Q3 25 | $73.9M | $150.1M | ||
| Q2 25 | — | $62.7M | ||
| Q1 25 | — | $96.3M | ||
| Q4 24 | — | $325.5M | ||
| Q3 24 | $63.2M | $80.0M | ||
| Q2 24 | — | $72.4M | ||
| Q1 24 | — | $87.3M |
| Q4 25 | — | 163.2% | ||
| Q3 25 | 26.5% | 71.3% | ||
| Q2 25 | — | 31.9% | ||
| Q1 25 | — | 51.2% | ||
| Q4 24 | — | 174.6% | ||
| Q3 24 | 25.2% | 42.2% | ||
| Q2 24 | — | 40.5% | ||
| Q1 24 | — | 49.8% |
| Q4 25 | — | 2.2% | ||
| Q3 25 | 0.1% | 0.2% | ||
| Q2 25 | — | 0.6% | ||
| Q1 25 | — | 1.4% | ||
| Q4 24 | — | 1.9% | ||
| Q3 24 | 0.0% | 0.6% | ||
| Q2 24 | — | 0.3% | ||
| Q1 24 | — | 0.5% |
| Q4 25 | -0.18× | 4.07× | ||
| Q3 25 | 1.03× | 1.94× | ||
| Q2 25 | 2.40× | 0.83× | ||
| Q1 25 | 1.07× | 1.42× | ||
| Q4 24 | 0.28× | 4.10× | ||
| Q3 24 | 1.93× | 1.20× | ||
| Q2 24 | 0.75× | 1.09× | ||
| Q1 24 | 1.76× | 1.23× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ACAD
| Nuplazid | $174.4M | 61% |
| Daybue | $109.6M | 39% |
CATY
Segment breakdown not available.
